{"id":"W2041310270","doi":"10.1517/14656566.2012.689130","title":"Sunitinib malate for the treatment of renal cell carcinoma","year":2012,"lang":"en","type":"review","venue":"Expert Opinion on Pharmacotherapy","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Sunitinib; Sunitinib malate; Medicine; Renal cell carcinoma; Tolerability; Tyrosine-kinase inhibitor; Vascular endothelial growth factor; Pazopanib; Oncology; Clinical trial; Dosing; Internal medicine; Pharmacology; Adverse effect; Cancer; VEGF receptors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001822686,0.0008451504,0.001950805,0.0002464503,0.0001324653,0.00001744575,0.0002587485,0.0002547227,0.0008117197],"category_scores_gemma":[0.000002830485,0.000443755,0.001693234,0.0002035736,0.00009888057,0.00004008565,0.000013695,0.0001993158,0.00007416357],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005024309,"about_ca_system_score_gemma":0.0002806742,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004253737,"about_ca_topic_score_gemma":2.962533e-7,"domain_scores_codex":[0.9974847,0.000206144,0.0008219891,0.0005329619,0.0004117864,0.0005424501],"domain_scores_gemma":[0.9975115,0.0007228823,0.0005506192,0.0008457459,0.0001001941,0.0002690438],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0007091796,0.001851163,0.000006359537,0.002111736,0.0008012716,0.00001180868,0.0006254031,6.770964e-7,0.0003480524,0.00003783327,0.003600575,0.9898959],"study_design_scores_gemma":[0.004951665,0.003826531,0.00001016068,0.001205841,0.0006497775,0.00006474386,0.00002406135,0.00001174194,0.01585542,0.000001762401,0.9730538,0.0003444883],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001150682,0.9915311,0.00004273477,0.0002125626,0.001508577,0.005341006,0.0001815483,0.00004949365,0.001017923],"genre_scores_gemma":[0.0003236858,0.9912241,0.000267175,0.0003102177,0.002680507,0.002428518,0.0004493153,0.0002174469,0.002099065],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9895514,"threshold_uncertainty_score":0.9998014,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.192132551629056,"score_gpt":0.4298720621045542,"score_spread":0.2377395104754982,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}